Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study
Last Updated: Monday, December 20, 2021
In an analysis of the phase III BELINDA trial, the chimeric antigen receptor T-cell therapy tisagenlecleucel was not found to improve event-free survival over the standard of care as a second-line treatment for patients with aggressive non-Hodgkin lymphoma (Abstract LBA-6).
Advertisement
News & Literature Highlights
